Esperion Therapeutics, Inc.
http://www.esperion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Esperion Therapeutics, Inc.
Health Plan Transparency Still At Issue, ICER Finds
In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.
Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables
The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.
Esperion Preps Nexletol/Nexlizet To Be ‘Clear Next Step’ After Statins
The company plans to ramp up its commercial infrastructure later this year, ahead of a labeling update based on positive cardiovascular outcomes trial data.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice